Campaign Launched by EPDA to Highlight Overlooked Symptoms of Parkinson's Disease

New Life With Parkinson's - Non-Motor Symptoms Campaign Builds on Parkinson's Awareness Campaign

GLASGOW, Scotland, September 30, 2010 - Today the European Parkinson's Disease Association (EPDA)
announces the launch of its pan-European awareness campaign, Life with
Parkinson's - Non-Motor Symptoms at the 2nd World Parkinson Congress in
Glasgow.

Recent surveys have revealed that close to 90% of people with
Parkinson's have at least one non-motor symptom, with about 25% having three
non-motor symptoms.1 Non-motor symptoms are a major cause of morbidity in
Parkinson's, yet are often under recognised.2

Susanna Lindvall, vice president of the EPDA, commented, "The
Life with Parkinson's - Non-Motor Symptoms campaign aims to strengthen
understanding of non-motor symptoms in Parkinson's disease among a wide range
of audiences including people with Parkinson's, their families and friends,
healthcare professionals and policy makers. We hope that the campaign will
help improve recognition and understanding of these symptoms so that medical
advice and treatment is sought as early as possible."

Parkinson's disease is a degenerative disorder of the brain
which can affect people's movement, resulting in the well-recognised symptoms
of tremor, stiffness, slowness of movement and impaired balance. An estimated
four million people worldwide live with the disease, which usually affects
people over the age of 60, however, more than 1 in 10 people with Parkinson's
are diagnosed before the age of 50 years.3

Less well known, but of equal importance, are the symptoms
that are not related to movement. These signs, referred to as 'non-motor
symptoms', can include loss of sense of smell, depression, sleep problems,
constipation, incontinence and pain. They can occur at any stage of the
disease and many of them precede a formal diagnosis of Parkinson's by several
years. These symptoms can come to dominate the condition as the disease
progresses, having an enormous impact on quality of life.

Jo Collinge from the UK, diagnosed with Parkinson's 1 year
ago, days before her 47th birthday, commented "I was both perplexed and
anxious when I first experienced non-motor symptoms. I was finding it
difficult to cope with life in general and had sleeping difficulties before
my motor symptoms started, I was unaware, at that stage, that they were
related to Parkinson's disease. When I realised that they were related, I
felt that all the pieces of the puzzle slotted together. A resource, such as
the Life with Parkinson's - Non-Motor Symptoms campaign, would have helped
both me and my family to understand what was happening and would have
prompted me to seek medical help immediately."

Indeed, a recent survey of over 5,000 members of the general
public from across Europe has highlighted why the Life with Parkinson's -
Non-Motor Symptoms campaign is urgently needed. Supported by a grant from
Teva Pharmaceuticals Limited and H. Lundbeck A/S, the results paint a
troubling picture of the lack of knowledge and understanding of non-motor
symptoms of Parkinson's.

Results from the survey show that while 62% of people
associate depression with Parkinson's, only 6% of people see this as a main
concern. Depression is a prominent non-motor symptom of Parkinson's affecting
40-50% of people. 91% of the general public do not think that they would feel
isolated with Parkinson's, despite the proven physical and psychological
effects it has on relationships, independence and confidence.

Commenting on these results, Mary Baker MBE, EPDA patron, EFNA
president and EBC vice president said "The results from this survey
highlights how little is understood about non-motor symptoms in Parkinson's.
With the Life with Parkinson's - Non-Motor Symptoms campaign, the EPDA aims
to fill knowledge gaps and help people recognise symptoms that may be a
result of Parkinson's. It will help encourage those who are experiencing
non-motor symptoms to see their physician in order to obtain an earlier
diagnosis and, if appropriate, start treatment. The sooner symptoms are
effectively managed, the less of an impact they will have on quality of life"

For more information about this campaign please go to
www.parkinsonsawareness.eu.com

1. Hinnell C, Chaudhuri KR. The Effect of Non-motor Symptoms
on Quality of Life in Parkinson's Disease. European Neurological Review
2009;4(2):29-33.

2. Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan
JC, Gronseth GS, et al. Practice Parameter: treatment of nonmotor symptoms of
Parkinson disease: report of the Quality Standards Subcommittee of the
American Academy of Neurology. Neurology 2010;74(11):924-31.

3. EPDA. Global Declaration.

Notes to Editors

Further supporting materials

For further media resources, please visit our Social Media Release site:
oursocialmedia.com/uk/epda-uk/epda-nms/

For broadcast-standard video supporting this press release, please visit
www.thenewsmarket.com/Lundbeck. If you are a first-time user, please
take a moment to register. In case you have any questions, please email
journalisthelp@thenewsmarket.com.

To keep up to date about new developments around the awareness campaign,
please join our Facebook page www.facebook.com/theEPDA. Please also
see myPDinfo (www.myPDinfo.com), an exciting online resource for
people with Parkinson's, their family and carers. The webpage contains
information about Parkinson's including disease background, medication guides
and daily observation diaries.

Development of Non-Motor Symptoms has been supported by an
unrestricted educational grant from H. Lundbeck A/S and Teva Pharmaceutical
Industries Limited.

European Parkinson's Disease Association (EPDA) has 44 member
organisations and is the advocate for the rights and needs of 1.2 million
people with Parkinson's and their families in Europe. Its aim is to raise
awareness to ensure that all people with Parkinson's and their families have
access to the right management and the right treatment at the right time. Its
vision it to enable a full life with Parkinson's while supporting the search
for a cure. For further information on the work of the EPDA please visit
www.epda.eu.com or contact: info@epda.eu.com.

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA),
headquartered in Israel, is among the top 20 pharmaceutical companies in the
world and is the leading generic pharmaceutical company. It develops,
manufactures and markets generic and innovative human pharmaceuticals and
active pharmaceutical ingredients. Over 80 percent of Teva's sales are in
North America and Western Europe. Teva's innovative R&D focuses on developing
novel drugs for diseases of the central nervous system. For more information,
please visit www.tevapharm.com.

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international
pharmaceutical company highly committed to improving the quality of life for
people suffering from central nervous system (CNS) disorders. For this
purpose Lundbeck is engaged in the research and development, production,
marketing and sale of pharmaceuticals across the world, targeted at disorders
like depression and anxiety, schizophrenia, insomnia, Huntington's,
Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen,
Denmark, and today employs over 5,500 people worldwide. Lundbeck is one of
the world's leading pharmaceutical companies working with CNS disorders. In
2008, the company's revenue was DKK 11.3 billion (approximately EUR 1.5
billion or USD 2.2 billion). For more information, please visit
www.lundbeck.com.

Media enquiries: Burson-Marsteller, London: Nicola Manomaiudom, +44(0)20-7300-6176, +44(0)77-8755-0579, nicola.manomaiudom at bm.com; Rachel Terry, +44(0)20-7300-6352, +44(0)78-8785-2275, rachel.terry at bm.com